-
Article
Open AccessCore-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
-
Article
Open AccessEuropean LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
We sought to appraise the value of overall response and salvage chemotherapy, inclusive of allogeneic hematopoietic stem cell transplant (AHSCT), in primary refractory acute myeloid leukemia (prAML). For estab...
-
Article
Open AccessPrognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients
Current prognostic models for myelodysplastic syndromes (MDS), including the Revised International Prognostic Scoring System (IPSS-R), do not account for host immunity. We retrospectively examined the prognost...
-
Article
Erratum: Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
-
Article
Open AccessMolecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
-
Article
Open AccessImetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
-
Article
Open AccessGenetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
-
Article
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib
There are several reports in LEUKEMIA on the efficacy of JAK2-inhibitors such as ruxolitinib, in persons with MPN-associated myelofibrosis. Few doubt these drugs reduce spleen size and relieve symptoms in many...
-
Article
Leukemia risk models in primary myelofibrosis: an International Working Group study
-
Article
Open AccessIPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
Recent studies suggest a powerful prognostic value for plasma cytokine levels in primary myelofibrosis (interleukin (IL)-2R, IL-8, IL-12, IL-15 and C–X–C motif chemokine 10 (CXCL10)) and large-cell lymphoma (I...
-
Article
A phase-2 trial of low-dose pomalidomide in myelofibrosis
In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). T...
-
Article
Open AccessRefined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
We have previously identified sole +9, 13q- or 20q-, as ‘favorable’ and sole +8 or complex karyotype as ‘unfavorable’ cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients...